Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2023-05-19 Sale | 2023-05-23 08:06 am | LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development | 4,300 | $216.91 | $932,707 | 12,946 (Direct) | View |
| 2023-02-21 Sale | 2023-02-23 09:54 am | LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development | 8,000 | $250.58 | $2,004,675 | 13,369 (Direct) | View |
| 2021-05-06 Sale | 2021-05-10 08:21 am | LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development | 2,500 | $276.55 | $691,375 | 7,844 (Direct) | View |
| 2020-11-04 Sale | 2020-11-06 09:06 am | LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development | 1,500 | $214.14 | $321,204 | 7,698 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2023-05-19 Exercise | 2023-05-23 08:06 am | 2021-02-04 2030-02-03 | LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development | 4,300 | $0 | 12,946 (Direct) | View |
| 2023-05-19 Exercise | 2023-05-23 08:06 am | N/A N/A | LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development | 4,300 | $182.51 | 12,946 (Direct) | View |
| 2023-03-30 Option Award | 2023-04-03 10:13 am | N/A N/A | LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development | 6,763 | $0 | 12,946 (Direct) | View |
| 2023-03-30 Tax Withholding | 2023-04-03 10:13 am | N/A N/A | LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development | 2,886 | $224.7 | 12,946 (Direct) | View |
| 2023-02-21 Exercise | 2023-02-23 09:54 am | 2021-02-04 2030-02-03 | LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development | 3,000 | $0 | 13,369 (Direct) | View |
| 2023-02-21 Exercise | 2023-02-23 09:54 am | N/A N/A | LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development | 3,000 | $182.51 | 13,369 (Direct) | View |
| 2023-02-11 Exercise | 2023-02-14 2:57 pm | N/A N/A | LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development | 483 | $0 | 17,070 (Direct) | View |
| 2023-02-13 Tax Withholding | 2023-02-14 2:57 pm | N/A N/A | LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development | 142 | $248.13 | 17,070 (Direct) | View |
| 2023-02-07 Option Award | 2023-02-09 12:02 pm | N/A N/A | LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development | 6,590 | $0 | 8,484 (Direct) | View |
| 2023-02-04 Exercise | 2023-02-07 2:51 pm | N/A N/A | LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development | 560 | $0 | 15,622 (Direct) | View |
| 2023-02-06 Tax Withholding | 2023-02-07 2:51 pm | N/A N/A | LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development | 164 | $244.5 | 15,622 (Direct) | View |
| 2023-02-02 Tax Withholding | 2023-02-06 3:45 pm | N/A N/A | LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development | 141 | $254.99 | 15,786 (Direct) | View |
| 2023-02-02 Exercise | 2023-02-06 3:45 pm | N/A N/A | LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development | 443 | $0 | 15,786 (Direct) | View |
| 2022-11-01 Tax Withholding | 2022-11-03 5:00 pm | N/A N/A | LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development | 892 | $222.56 | 15,927 (Direct) | View |
| 2022-11-01 Exercise | 2022-11-03 5:00 pm | N/A N/A | LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development | 2,007 | $0 | 15,927 (Direct) | View |
| 2022-03-27 Option Award | 2022-03-29 12:04 pm | N/A N/A | LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development | 3,707 | $0 | 11,915 (Direct) | View |
| 2022-03-28 Tax Withholding | 2022-03-29 12:04 pm | N/A N/A | LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development | 1,648 | $276.42 | 11,915 (Direct) | View |
| 2022-02-11 Option Award | 2022-02-15 4:42 pm | N/A N/A | LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development | 6,550 | $0 | 25,081 (Direct) | View |
| 2022-02-12 Exercise | 2022-02-15 4:42 pm | N/A N/A | LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development | 317 | $0 | 25,081 (Direct) | View |
| 2022-02-14 Tax Withholding | 2022-02-15 4:42 pm | N/A N/A | LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development | 108 | $272.68 | 25,081 (Direct) | View |
| 2022-02-04 Exercise | 2022-02-08 11:13 am | N/A N/A | LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development | 560 | $0 | 13,418 (Direct) | View |
| 2022-02-04 Tax Withholding | 2022-02-08 11:13 am | N/A N/A | LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development | 165 | $277.48 | 13,418 (Direct) | View |
| 2022-02-02 Tax Withholding | 2022-02-04 09:44 am | N/A N/A | LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development | 144 | $273.18 | 13,583 (Direct) | View |
| 2022-02-02 Exercise | 2022-02-04 09:44 am | N/A N/A | LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development | 443 | $0 | 13,583 (Direct) | View |
| 2021-11-01 Exercise | 2021-11-03 11:47 am | N/A N/A | LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development | 2,007 | $0 | 13,727 (Direct) | View |
| 2021-11-01 Tax Withholding | 2021-11-03 11:47 am | N/A N/A | LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development | 898 | $288.78 | 13,727 (Direct) | View |
| 2021-04-03 Exercise | 2021-04-06 12:18 pm | N/A N/A | LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development | 1,010 | $0 | 17,125 (Direct) | View |
| 2021-04-03 Tax Withholding | 2021-04-06 12:18 pm | N/A N/A | LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development | 452 | $252.67 | 17,125 (Direct) | View |
| 2021-03-27 Option Award | 2021-03-30 6:42 pm | N/A N/A | LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development | 2,104 | $0 | 9,786 (Direct) | View |
| 2021-03-27 Tax Withholding | 2021-03-30 6:42 pm | N/A N/A | LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development | 790 | $251.58 | 9,786 (Direct) | View |
| 2021-02-12 Exercise | 2021-02-17 4:25 pm | N/A N/A | LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development | 581 | $0 | 24,371 (Direct) | View |
| 2021-02-12 Tax Withholding | 2021-02-17 4:25 pm | N/A N/A | LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development | 180 | $238.26 | 24,371 (Direct) | View |
| 2021-02-04 Exercise | 2021-02-08 3:39 pm | N/A N/A | LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development | 560 | $0 | 16,443 (Direct) | View |
| 2021-02-04 Tax Withholding | 2021-02-08 3:39 pm | N/A N/A | LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development | 187 | $223.78 | 16,443 (Direct) | View |
| 2021-02-02 Option Award | 2021-02-04 5:14 pm | N/A N/A | LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development | 5,930 | $0 | 13,532 (Direct) | View |
| 2020-11-02 Tax Withholding | 2020-11-04 5:40 pm | N/A N/A | LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development | 895 | $207.23 | 16,800 (Direct) | View |
| 2020-11-02 Exercise | 2020-11-04 5:40 pm | N/A N/A | LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development | 2,006 | $0 | 16,800 (Direct) | View |
| 2020-04-03 Exercise | 2020-04-07 4:21 pm | N/A N/A | LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development | 1,010 | $0 | 17,695 (Direct) | View |
| 2020-04-03 Tax Withholding | 2020-04-07 4:21 pm | N/A N/A | LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development | 372 | $113.31 | 17,695 (Direct) | View |
| 2020-03-30 Option Award | 2020-04-01 2:29 pm | N/A N/A | LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development | 3,402 | $0 | 7,449 (Direct) | View |
| 2020-03-30 Tax Withholding | 2020-04-01 2:29 pm | N/A N/A | LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development | 1,014 | $131.95 | 7,449 (Direct) | View |
| 2020-02-12 Tax Withholding | 2020-02-14 3:48 pm | N/A N/A | LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development | 159 | $187.51 | 26,613 (Direct) | View |
| 2020-02-12 Exercise | 2020-02-14 3:48 pm | N/A N/A | LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development | 579 | $0 | 26,613 (Direct) | View |
| 2020-02-07 Tax Withholding | 2020-02-11 1:43 pm | N/A N/A | LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development | 103 | $182.33 | 15,838 (Direct) | View |
| 2020-02-07 Exercise | 2020-02-11 1:43 pm | N/A N/A | LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development | 337 | $0 | 15,838 (Direct) | View |
| 2020-02-04 Option Award | 2020-02-06 2:33 pm | N/A N/A | LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development | 8,980 | $0 | 18,834 (Direct) | View |